Orlistat reduces features of the metabolic syndrome: the XENDOS study.
D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000517:prevention & control; D006801:Humans; D007783:Lactones / Q000627:therapeutic use*; D024821:Metabolic Syndrome / Q000188:drug therapy*; D000077403:Orlistat
D019440:Anti-Obesity Agents; D007783:Lactones; D000077403:Orlistat